Intrathecal chemotherapy with antineoplastic agents in children

Paediatric Drugs

Volumn 3, Issue 4, 2001, Pages 237-246

  Ruggiero, Antonio ^a   Conter, Valentino ^b   Milani, Marina ^b   Biagi, Ettore ^b   Lazzareschi, Ilaria ^a   Sparano, Paola ^b   Riccardi, Riccardo ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; DEXAMETHASONE; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; RADIOISOTOPE; THIOTEPA; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; BLOOD BRAIN BARRIER; BRAIN CANCER; BRAIN LEUKEMIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL INFILTRATION; CHILDHOOD CANCER; CLINICAL TRIAL; DOSE RESPONSE; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; LEUKEMIA; LEUKEMIC MENINGITIS; LYMPHOMA; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RELAPSE; REVIEW;

EID: 0035028543     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200103040-00001     Document Type: Review

References (71)

1. Prevention of central nervous system leukemia by irradiation
2. Chemotherapy of acute lymphocytic leukaemia of childhood
3. Central nervous system prophylaxis in children with low risk acute lymphoblastic leukemia
4. Central nervous system relapse prevention in 1165 standard-risk children with acute lymphoblastic leukemia in five BFM trials
5. Pilot trial HIT-SKK'87/HIT-SKK'92: A retrospective neuropsychological study in children less than 3 years of age with medulloblastoma
6. The blood-brain barrier
7. A comparison of the construction of intercellular junctions in the CNS of vertebrates
8. Morphology of blood-brain interfaces
9. The blood-brain barrier: Facts and questions
10. Induction of bloodbrain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors
11. The P-glycoprotein multidrug transporter
12. Pharmacological insights from P-glycoprotein knockout mice
13. Pharmacokinetics selectivity of action related to physiochemical properties and kinetic patterns of anticancer drugs
14. Chemotherapy. The agents in current use
15. Pharmacodynamics and the blood-brain barrier in modern concepts in brain tumor therapy: Laboratory and clinical investigations
16. Blood-brain barrier: Interface between internal medicine and the brain
17. Regional therapy: An overview
18. Pharmacologic approaches to the treatment of central nervous system malignancy
19. Pharmacology of antineoplastic agents in cerebrospinal fluid
20. Central nervous system therapy and combination chemotherapy of childhood lymphocytic leukemia
21. The influence of previous lumbar puncture and pneumoencephalography on the incidence of unsuccessful radioisotope cisternography
22. Concentration x time methotrexate via a subcutaneous reservoir: A less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms
23. Influence of body position on ventricular cerebrospinal fluid methotrexate concentration following intralumbar administration
24. Implantable devices for chronic access and drug delivery to the central nervous system
25. Intraventricular versus intralumbar methotrexate for central nervous system leukemia: Prolonged remission with the Ommaya reservoir
26. Intrathecal chemotherapy: Brain tissue profiles after ventriculo-cisternal perfusion
27. Methotrexate II: Use in pediatric chemotherapy
28. 111Indium-DTPA ventriculography
29. Reduction in central nervous system leukemia with a pharmacokinetically derived intrathecal methotrexate dosage regimen
30. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in menigeal leukemia
31. Clinical studies on the central nervous system pharmacology of methotrexate
32. Intrathecal chemotherapy for treatment of overt meningeal leukemia: Comparison between intraventricular and traditional intralumbar route
33. Change in transfer rate of methotrexate from spinal fluid to plasma during intrathecal therapy in children and adults
34. Clinical pharmacology of intrathecal methotrexate. II: An improved dosage regiman derived from age-related pharmacokinetics
35. Prevention and treatment of meningeal leukemia in children
36. Central nervous system pharmacokinetics of high-dose cytosine arabinoside
37. The pharmacokinetics of cytosine arabinoside in the plasma and cerebrospinal fluid during conventional and high-dose therapy
38. Studies of the enzymatic deamination of cytosine arabinoside. I: Enzyme distribution and species specificity
39. Distribution of kinase and deaminase of 1-β-Darabinofuranosyl-cytosine in tissues of man and mouse
40. Cytosine arabinoside cerebrospinal fluid kinetics
41. High-performance liquid chromatographic assay for cytosine arabinoside and uracil arabinoside in cerebrospinal fluid and plasma
42. Fate of the predominant phospholipid component of DepoFoam drug delivery matrix after intrathecal administration of sustainedrelease encapsulated cytarabine in rats
43. Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis
44. Pharmacokinetics of intralumbar DTC 101 for the treatment of leptomeningeal metastases
45. Intrathecal depot cytarabine therapy: A welcome addition to a limited armamentarium
46. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in goodrisk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: A Pediatric Oncology Group study
47. Differences in cerebrospinal fluid penetration of corticosteroids: Possible relationship to the prevention of meningeal leukemia
48. Lower incidence of meningeal leukemia when prednisone is replaced by dexamethasone in the treatment of acute lymphocytic leukemia
49. Dexamethasone in the treatment of meningeal leukemia
50. Chronic intrathecal administration of dexamethasone sodium phosphate: Pharmacokinetics and neurotoxicity in an animal model
51. Current pharmacological treatment approaches to central nervous system leukaemia
52. Pharmacokinetics of intraventricular and intravenous N, N′, N″-triethylenethiophosphoramide (thiotepa) in rhesus monkeys and humans
53. Intrathecal 6-mercaptopurine: Preclinical pharmacology, phase I/II trial, and pharmacokinetics study
54. New cytotoxic drugs for intrathecal administration
55. Treatment of neoplastic meningitis with intrathecal temozolomide
56. Intrathecal 131Ilabeled antitenascin monoclonal antibody 81 C6 treatment of patients with leptomenigeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: Phase I trial results
57. Dose escalation with repeated intrathecal injections of 131I-labelled mabs for the treatment of central nervous system malignancies
58. Neurologic complications of chemotherapy
59. Neurotoxicity of antineoplastic drugs
60. Paraplegia following intrathecal chemotherapy
61. The central nervous system in childhood leukemia: II. Subacute leukoencephalopathy
62. The acute management of intrathecal methotrexate overdose: Pharmacologic rationale and guidelines
63. Pharmacokinetics and biochemical effects of a fatal intrathecal methotrexate overdose
64. Errors involving pediatric patients receiving chemotherapy: A literature review
65. Cerebrospinal fluid exchange after intrathecal methotrexate overdose: A report of two cases
66. Successful treatment on intrathecal methotrexate overdose by using ventriculolumbar perfusion and intrathecal instillation of carboxypeptidase G2
67. Seizures following intrathecal cytosine arabinoside in young children with acute lymphoblastic leukemia
68. Paraplegia following intrathecal cytosine arabinoside
69. Cerebrospinal fluid lavage in the treatment of inadvertent intrathecal vincristine injection
70. Fatality resulting from intraventricular vincristine administration
71. Massive intrathecal overdose: 'check the label twice!'